Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials

Eur J Prev Cardiol. 2022 May 25;29(7):e243-e245. doi: 10.1093/eurjpc/zwab221.

Authors

Mei Qiu¹, Xu-Bin Wei², Wei Wei³

Affiliations

¹ Department of General Medicine, Shenzhen Longhua District Central Hospital, Guanlan Avenue 187, Longhua District, Shenzhen 518110, China.
² Department of Cardiology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China.
³ Department of Pharmacy, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China.

PMID: 34939100
DOI: 10.1093/eurjpc/zwab221

No abstract available

Publication types

Meta-Analysis

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / diagnosis
Diabetes Mellitus, Type 2* / drug therapy
Exenatide / adverse effects
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / therapeutic use

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Glucagon-Like Peptide 1
Exenatide